Recombinant Human MAPT protein(Ala2-Leu352), His-tagged

• Cat.No.: MAPT-528H
• Product Overview: Recombinant Human MAPT (NP_058525.1) (Ala2-Leu352) was expressed in E. coli with a polyhistide tag at the N-terminus.

Specification

• Source: E. coli
• Species: Human
• Tag: N-His
• Protein length: Ala2-Leu352
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The recombinant human MAPT consists of 367 amino acids and predicts a molecular mass of 38.7 KDa. It migrates as an approximately 40-50 KDa band in SDS-PAGE under reducing conditions.
• Purity: > 85 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: MAPT microtubule-associated protein tau [ Homo sapiens ]
• Official Symbol: MAPT
• Synonyms: MAPT; microtubule-associated protein tau; DDPAC, MAPTL; FLJ31424; FTDP 17; G protein beta1/gamma2 subunit interacting factor 1; MGC138549; microtubule associated protein tau; isoform 4; MSTD; MTBT1; MTBT2; PPND; tau; TAU; PHF-tau; paired helical filament-tau; neurofibrillary tangle protein; microtubule-associated protein tau, isoform 4; G protein beta1/gamma2 subunit-interacting factor 1; DDPAC; MAPTL; FTDP-17
• Gene ID: 4137
• mRNA Refseq: NM_001123066
• Protein Refseq: NP_001116538
• MIM: 157140
• UniProt ID: P10636

Reviews

07/22/2022

Western-blot experiments using MAPT as a target have shown highly reproducible results.

08/08/2020

This stability of MAPT is very good and can maintain its original properties even after multiple uses.

09/15/2019

MAPT's purity and consistency make it a top choice for Western-blot experiments.

Q&As

How to assess the degree of abnormal aggregation of MAPT protein?

The degree of abnormal aggregation of MAMAP proteins can be assessed by a variety of methods, such as immunohistochemistry, immunofluorescence staining, Western blot, etc. These methods can detect and quantify abnormally aggregated MAPT proteins.

What is the relationship between MAPT protein and nerve cytoskeleton?

The MAPT protein is closely related to the nerve cytoskeleton. It is involved in regulating axon formation and maintenance, cytosolic flow, and the normal function of neurons by binding and stabilizing microtubules.

What are the interactions of the MAPT protein with other proteins in the nervous system?

MAPT protein interacts with other proteins in the nervous system, such as α-synuclein, β-kinigin, etc. These interactions may be involved in regulating the structure and function of neurons.

Is there a mechanism that regulates the expression of MAPT protein?

Yes, the expression of MAPT protein is affected by a variety of regulatory mechanisms, including transcriptional regulation, splicing regulation, phosphorylation regulation, etc. These regulatory mechanisms are essential for maintaining normal MAPT protein levels and function.

What are the future directions for MAPT protein research?

Future research directions include further elucidating the mechanism of abnormal aggregation and phosphorylation of MAPT protein, exploring the pathogenesis of genetic diseases associated with MAPT gene, finding therapeutic strategies to intervene in abnormal aggregation of MATT, and developing biomarkers related to MAPT protein for early diagnosis and therapeutic monitoring.

How about the applications of MAPT protein in clinical diagnosis?

The MAPT protein plays an important role in clinical diagnosis. By measuring the level of the MAPT protein in the blood or cerebrospinal fluid, it can help identify different types of neurodegenerative diseases, such as Alzheimer's disease and prefrontal temporal dementia.